Otonomy Stock

Otonomy FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Otonomy (OTIC) as of Sep 14, 2026 is 83.45 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 87.19 % — a change of -4.28% (lower).

FCF Conversion

83.45 %

YoY

-4.28%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Otonomy is 2026 83.45 % . FCF Conversion Rate (FCF/EBITDA) of Otonomy was 2025 87.19 % . It decreases by -4.28% lower compared to the previous year.

The Otonomy FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
83.90 USD
Jan 1, 2015
84.19 USD
Jan 1, 2016
87.59 USD
Jan 1, 2017
84.96 USD
Jan 1, 2018
77.29 USD
Jan 1, 2019
84.22 USD
Jan 1, 2020
87.19 USD
Jan 1, 2021
83.45 USD
The Otonomy FCF Conversion history
YEARFCF ConversionYoY
83.45 %-4.28%
87.19 %+3.52%
84.22 %+8.97%
77.29 %-9.02%
84.96 %-3.01%
87.59 %+4.04%
84.19 %+0.35%
83.90 %
Access this data via the Eulerpool API

Otonomy Stock analysis

What does Otonomy do? Otonomy Inc is a biopharmaceutical company focused on developing innovative therapies for inner ear disorders. The company was founded in 2008 in San Diego, California and has since made significant advancements to bring its products to market. Otonomy's business model is based on identifying unmet medical needs in the field of otolaryngology. The company develops and markets FDA-approved ear medications that are designed in new and innovative ways to improve the treatment of hearing and balance disorders. The different divisions of Otonomy include clinical research, product development, manufacturing, and distribution. The company has an experienced team of scientists, engineers, clinical researchers, and managers who work closely together to develop and bring Otonomy's pipeline of drug candidates to market. The company has launched a number of products targeting the needs of patients with inner ear disorders. For example, the medication Otiprio was developed to treat otitis media, an inflammation of the middle ear. Otiprio is delivered directly into the ear during a minor surgery, where it quickly acts to eliminate the inflammation. Another one of Otonomy's products is Otividex, a medication developed to treat patients with Meniere's disease. This condition is a rare inner ear disorder that causes dizziness, tinnitus, and hearing loss. Otividex is also delivered directly into the ear and has shown to alleviate the dizziness symptoms and improve hearing. In recent years, Otonomy has also developed a new technology called OTO-413, which aims to improve hearing by regenerating damaged hair cells in the inner ear. The company has successfully conducted clinical trials with OTO-413 and plans to further explore and develop the technology. Otonomy has also formed partnerships with other companies and organizations in recent years to further develop its technologies and bring new products to market. For example, the company has entered into a collaboration agreement with Merck to develop new therapies for inner ear disorders. Otonomy also collaborates with a number of academic institutions and research facilities to further explore and develop the potential of its technologies. Overall, Otonomy Inc is an innovative and dynamic company dedicated to developing new therapies for inner ear disorders. With a strong pipeline of drug candidates and a dedicated group of scientists and researchers, the company is well positioned to make significant advancements in the treatment of hearing and balance disorders in the coming years. Otonomy is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Otonomy stock

FCF Conversion Rate (FCF/EBITDA) of Otonomy is 83.45 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Otonomy changed from 87.19 % to 83.45 %, representing a -4.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Otonomy since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Otonomy with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Otonomy

All Key Metrics — Otonomy